Canada markets close in 24 minutes
  • S&P/TSX

    20,474.20
    -127.90 (-0.62%)
     
  • S&P 500

    4,431.81
    -41.94 (-0.94%)
     
  • DOW

    34,556.28
    -195.04 (-0.56%)
     
  • CAD/USD

    0.7846
    -0.0040 (-0.51%)
     
  • CRUDE OIL

    72.02
    -0.59 (-0.81%)
     
  • BTC-CAD

    60,291.29
    -833.84 (-1.36%)
     
  • CMC Crypto 200

    1,198.53
    -27.00 (-2.20%)
     
  • GOLD FUTURES

    1,752.90
    -3.80 (-0.22%)
     
  • RUSSELL 2000

    2,225.80
    -7.11 (-0.32%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • NASDAQ

    15,027.16
    -154.77 (-1.02%)
     
  • VOLATILITY

    20.43
    +1.74 (+9.31%)
     
  • FTSE

    6,963.64
    -63.84 (-0.91%)
     
  • NIKKEI 225

    30,500.05
    +176.71 (+0.58%)
     
  • CAD/EUR

    0.6686
    -0.0012 (-0.18%)
     

FREQ LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Frequency Therapeutics, Inc.

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York--(Newsfile Corp. - July 30, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Frequency Therapeutics, Inc. ("Frequency Therapeutics") (NASDAQ: FREQ) between November 16, 2020 and March 22, 2021.

If you suffered a loss, contact us at the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/frequency-therapeutics-inc-loss-submission-form?prid=18127&wire=5



Allegations against FREQ include that the Company made materially false and/or misleading statements and/or failed to disclose that: the Company's Phase 2a trial results failed to live up to the Company's expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322's potential. These statements materially misled the market and artificially inflated the value of Frequency's common stock.

If you suffered a loss in Frequency Therapeutics you have until August 2, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/91759

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting